Evaluating T Cells in Patients with Antisynthetase Syndrome and Lung Disease
Evaluation of Antigen-specific Th1 and T17 Cells, ILC and MAIT in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
This study is trying to see if certain immune cells in the lungs and blood of people with antisynthetase syndrome and lung disease can help us understand how severe their condition is and how they might respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 6 sites (Dijon and 5 other locations) |
| Trial ID | NCT05984394 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with antisynthetase syndrome (AS) who also have interstitial lung disease (ILD). It aims to evaluate the presence of antigen-specific Th1 and Th17 cells, as well as innate lymphoid cells (ILC) and mucosal-associated invariant T cells (MAIT) in bronchoalveolar fluid and peripheral blood. The study hypothesizes that these immune cells are associated with the severity of ILD and could predict treatment responses. By understanding these associations, the study seeks to inform potential targeted therapies for AS patients with ILD.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a new diagnosis of antisynthetase syndrome accompanied by interstitial lung disease.
Not a fit: Patients with alternative diagnoses for their interstitial lung disease or those who have received corticosteroids or immunosuppressive treatments in the past three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with antisynthetase syndrome and interstitial lung disease.
How similar studies have performed: While the specific approach of evaluating antigen-specific T cells in this context may be novel, related studies have shown promise in understanding immune responses in autoimmune diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with new diagnosis of AS with ILD Exclusion Criteria: * Patient with ILD differential diagnosis * Corticosteroid treatment, immunosuppresive or immunomodulatory drugs in the past 3 months before diagnosis
Where this trial is running
Dijon and 5 other locations
- Bernard Bonnotte — Dijon, France (Recruiting)
- Julien Campagne — Metz, France (Recruiting)
- Paul Decker — Nancy, France (Recruiting)
- Olivier Benveniste — Paris, France (Not_yet_recruiting)
- Loïs Bolko — Reims, France (Recruiting)
- Alain Meyer — Strasbourg, France (Recruiting)
Study contacts
- Principal investigator: Paul Decker, MD — Central Hospital, Nancy, France
- Study coordinator: Paul Decker, MD
- Email: p.decker@chru-nancy.fr
- Phone: +33383157240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.